| Literature DB >> 22457771 |
Asa Håkansson1, Camilla Bränning, Göran Molin, Diya Adawi, Marie-Louise Hagslätt, Bengt Jeppsson, Margareta Nyman, Siv Ahrné.
Abstract
Long-term colonic inflammation promotes carcinogenesis and histological abnormalities of the liver, and colorectal tumours frequently arise in a background of dysplasia, a precursor of adenomas. Altered colonic microbiota with an increased proportion of bacteria with pro-inflammatory characteristics, have been implicated in neoplastic progression. The composition of the microbiota can be modified by dietary components such as probiotics, polyphenols and dietary fibres. In the present study, the influence of probiotics in combination with blueberry husks on colorectal carcinogenesis and subsequent liver damage was evaluated.Colorectal tumours were induced in rats by cyclic treatment with dextran sulphate sodium (DSS). Blueberry husks and a mixture of three probiotic strains (Bifidobacterium infantis DSM 15159, Lactobacillus gasseri, DSM 16737 and Lactobacillus plantarum DSM 15313) supplemented a basic diet fortified with oats. The condition of the rats was monitored using a disease activity index (DAI). A qualitative and quantitative histological judgement was performed on segments of distal colon and rectum and the caudate lobe of the liver. The formation of short-chain fatty acids, bacterial translocation, the inflammatory reaction and viable count of lactobacilli and Enterobaceriaceae were addressed.Blueberry husks with or without probiotics significantly decreased DAI, and significantly reduced the number of colonic ulcers and dysplastic lesions. With a decreased proportion of blueberry husk in the diet, the probiotic supplement was needed to achieve a significant decrease in numbers of dysplastic lesions. Probiotics decreased faecal viable count of Enterobacteriaceae and increased that of lactobacilli. Blueberry husks with or without probiotics lowered the proportion of butyric acid in distal colon, and decreased the haptoglobin levels. Probiotics mitigated hepatic injuries by decreasing parenchymal infiltration and the incidence of stasis and translocation. The results demonstrate a dietary option for use of blueberry husks and probiotics to delay colonic carcinogenesis and hepatic injuries in the rat model.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22457771 PMCID: PMC3311639 DOI: 10.1371/journal.pone.0033510
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Diet composition.
| Component | C | P | 2B | 2BP | B | BP |
| Oat bran | 291 | 291 | - | - | 145 | 145 |
| Blueberry husks (B) | - | - | 122 | 122 | 61 | 61 |
| Basal mixture | 369.2 | 369.2 | 369.2 | 369.2 | 369.2 | 369.2 |
| Wheat starch | 380 | 380 | 549 | 549 | 465 | 465 |
| Probiotics (P) | - | + | - | + | - | + |
Composition of diets (g/kg dwb) given to rats in the following groups: Group 1, active control (C); Group 2, probiotics (P); Group 3, blueberry husks (2B); Group 4, blueberry husks and probiotics (2BP), reduced amount of blueberry husks (B), and reduced amount of blueberry husks and probiotics (BP).
Corresponding to 50 g dietary fibre/kg diet (dwb).
Corresponding to 25 g dietary fibre/kg diet (dwb).
Containing (g/kg dwb) 160 casein, 1.2 DL-methionine, 50 maize oil, 48 mineral mixture (Containing (g kg−1) 0.55 CuSO4⋅H2O, 2.0 ZnSO4⋅7H2O, 498 KH2PO4, 258 NaH2PO4⋅2H2O, 487 CaCO3, 0.1 KI, 86 MgSO4, 12 FeSO4⋅7H2O, 5 MnSO4⋅H2O, 0.03 CoCl⋅6H2O, 153 NaCl, 0.02 CrCl3⋅6H2O, 0.02 Na2Se), 8 vitamin mixture (Containing (g kg−1) 0.62 menadion, 2.5 thiamin hydrochloride, 2.5 riboflavin, 1.25 pyridoxin hydrochloride, 6.25 calcium pantothenate, 6.25 nicotinic acid, 0.25 folic acid, 12.5 inositol, 1.25 p-aminobenzoic acid, 0.05 biotin, 0.00375 cyanocobalamin, 0.187 retinol palmitate, 0.00613 calciferol, 25 d-α- tocopheryl acetate, 941.25 maize starch), 2 choline chloride, 100 sucrose.
Wheat starch (Cerestar, Krefeld, Germany).
+Freeze-dried Bifidobacterium infantis DSM 15159 ( = CURE21; dose, 2⋅109 CFU/d), Lactobacillus gasseri DSM 16737 ( = VPG44; dose, 1⋅109 CFU/d) and Lactobacillus plantarum DSM 15313 ( = HEAL19; dose, 3⋅109 CFU/d) were added to the diet.
Figure 1Disease activity index.
Disease activity index (DAI) during the 11 cycles of DSS administration. DAI scores are expressed as medians (25 and 75 percentiles). Significant differences are expressed versus the C group. Cycle 1: **P<0.01 for groups 2B, 2BP and B; Cycle 2: **P<0.01 for groups B and BP, *** P<0.001 for groups 2B and 2BP groups; Cycle 3: *P<0.05 for group P, **P<0.001 for group B group, ***P<0.001 for groups 2B, 2BP and BP; Cycle 4: *P<0.05 for group BP, ***P<0.001 for groups 2B and 2BP; Cycle 5: **P<0.01 for group B group, ***P<0.001 for groups 2B, 2BP, and BP; Cycle 6: *P<0.05 for group B, **P<0.01 for group BP,***P<0.001 for groups 2B and BP; Cycle 7: *P<0.05 for group B, **P<0.01 for groups 2B and B, ***P<0.001 for groups 2BP and BP; Cycle 8: *P<0.05 for group BP, **P<0.01 for groups 2B and B, ***P<0.001 for group 2BP; Cycle 9: *P<0.05 for groups 2B, 2BP, B, BP; Cycle 10, *P<0.05 for group B, **P<0.01 for groups 2B and 2BP; Cycle 11: *P<0.05 for groups 2B, 2BP, B, BP.
Figure 2Concentrations of haptoglobin.
Haptoglobin concentrations (mg/ml) in blood during the 11 cycles of DSS administration. Concentrations are expressed as medians (25 and 75 percentiles). Significant differences are expressed versus the C group. Base line: *P<0.05 for group B, **P≤0.01 for group 2B group, ***P<0.001 for group 2BP. DSS cycle 1: *P<0.05 for group BP. DSS cycle 5: *P<0.05 for group 2B. DSS cycle 10: *P<0.05 for group 2B. Pure water cycle (W1): **P<0.01 for group B; Water cycle 5 (W5) *P<0.05 for group 2B group.
Figure 5Quantification of dysplastic lesions.
Number of dysplastic lesions in colon and rectum classified as low grade dysplasia in different treatment groups. * denotes P<0.05 compared to group C.
Figure 6Quantification of colonic and rectal ulcers.
Number of ulcers of colonic and rectal mucosa in different treatment groups. ** denotes P≤0.01 and * denotes P<0.05 compared to group C.
Figure 11Faecal load of Enterobacteriaceae.
Viable count of Enterobacteriaceae (log CFU/g faecal sample) *P<0.05, **P<0.01, *** P≤0.001 compared to group C. By the addition of probiotics: group C vs group P **P<0.01; group 2B vs group 2BP #P≤0.05; B group vs BP group *P<0.05.
Figure 12Faecal load of lactobacilli.
Viable count of lactobacilli (log CFU/g faecal sample)*P<0.05, **P<0.01, ***P≤0.001 compared to group C. A decrease was found in group 2B *** P≤0.001 compared to group C. By the addition of probiotics: 2B group vs 2BP group ***P≤0.001, and B vs BP group *P<0.05.
Evaluation of liver injury (Scoring values).
| Scoring values | |||||
| Groups | Steatosis | Cellinfiltration | Cellinfiltration | Stasis | Loss of parenchyma |
| C | 10/24 (41.7%) | 2/24 (8.3%) | 16/24 (66.7%) | 8/24 (38.1%) | 6/18 (33.3%) |
| P | 20,5/24*# (85.4%) | 4/24 (16.7%) | 16/24 (66.7%) | 8/15 (53.3%) | 4/24 (16.7%) |
| 2B | 5/24 (20.8%) | 0/24 | 15/24 (62.5%) | 12/24 (50.0%) | 10/21 (47.6%) |
| 2BP | 15/24# (62.5%) | 0/24 | 10/24* (41.7%) | 8/24 (33.3%) | 3/24 (12.5%) |
| B | 6/15 (40.0%) | 1/15 (6.7%) | 6/15* (40.0%) | 0/12 | 0/12 |
| BP | 16.5/21*# (78.6%) | 1/18 (5.6%) | 4/18* (22.2%) | 0/18 | 0/18 |
Liver specimens were histologically evaluated for the degree of steatosis, infiltrating inflammatory cells in steatotic and non-steatotic areas, vascular stasis and loss of liver parenchyma. The status of the livers of different groups is expressed as scoring values (degree of scoring and received value/maximum value). Between brackets are the percentages of the values.
Cellinfiltration around CV within steatotic areas.
Cellinfiltration elsewhere in the parenchyma.
Degree of scoring: * denotes P<0.05 compared with the C group.
Statistical comparison of the total received score compared to maximum score: # denotes P<0.01 compared to rats fed diets without bacteria.
Evaluation of liver injury (Incidence).
| Incidence | |||||
| Groups | Steatosis | Cellinfiltration | Cellinfiltration | Stasis | Loss of parenchyma |
| C | 8/8 | 1/8 | 8/8 | 4/7 | 3/6 |
| P | 8/8 | 2/8 | 8/8 | 4/5 | 2/8 |
| 2B | 4/8 * | 0/8 | 8/8 | 6/8 | 5/7 |
| 2BP | 8/8 | 0/8 | 7/8 | 4/8 | 2/8 |
| B | 3/5 | 1/5 | 5/5 | 0/4 | 0/4 |
| BP | 7/7 | 1/6 | 4/6 | 0/6 * | 0/6 |
Liver specimens were histologically evaluated for the incidence of steatosis, infiltrating inflammatory cells in steatotic and non-steatotic areas, vascular stasis and loss of liver parenchyma. The status of the livers of different groups is expressed as incidence of phenomena.
Cellinfiltration around CV within steatotic areas.
Cellinfiltration elsewhere in the parenchyma.
Incidence: * denotes P<0.05 compared with the C group.
Incidence of translocations and identified isolates from the livers.
| Groups | Translocation | Identity of isolate | Similarity to strain of known identity (%) |
| C | 3/8; 2/8; 4/8 |
| 99 (2 isolates) |
|
| 99 | ||
|
| 99 | ||
|
| 96 | ||
|
| 99, 93 | ||
|
| 100 | ||
|
| 100 | ||
|
| 100 | ||
|
| 100 (2 isolates) | ||
| P | 0/8; 2/8; 1/8 |
| 100 |
|
| 99 | ||
| 2B | 1/8; 1/8; 3/8 |
| 99 |
|
| 99 (2 isolates), 100 | ||
|
| 100 | ||
|
| 99 | ||
|
| 97 | ||
|
| 100 | ||
|
| 99 | ||
|
| 99 | ||
| 2BP | 0/8; 3/8; 3/8 |
| 99 |
|
| 99 | ||
|
| 100 | ||
|
| 100 | ||
|
| 98 | ||
| B | 0/6; 1/6; 4/6 |
| 99 |
|
| 98 | ||
|
| 100 | ||
|
| 99 | ||
|
| 99 | ||
| BP | 0/8; 0/8; 0/8 * | - | - |
Thirty-four isolates were subjected to 16 S rDNA sequencing and the similarity levels for each isolate are shown in the table. Translocation is mentioned as incidence of phenomena/total number of animals. Isolates were received from Rogosa agar/Brain Heart Infusion agar (incubated anaerobically)/Brain Heart Infusion agar (incubated aerobically). Between brackets are species with the same sequence similarity as the before mentioned.
Incidence: * denotes P<0.05 compared with the C group.
Lactobacillus animalis (L. animalis), Lactobacillus apodemi (L. apodemi), Kocuria rhizophila (K. rhizophila), Lactobacillis frumenti (L. frumenti), Lactobacillus antri (L. antri), Lactobacillus gasseri (L. gasseri), Micrococcus luteus (M. luteus), Clostridium ramosum (C. ramosum), Staphylococcus warneri (S. warneri), Leifsonia xyli subsp. cynodontis (L. xyli subsp. cynodontis), Enterococcus casseliflavus (E. casseliflavus), Clostridium perfringens (C. perfringens), Paenibacillus lautus (P. lautus), Kocuria rosea (K. rosea), Corynebacterium lipophiloflavum (C. lipophiloflavum), Clostridium subterminale (C. subterminale), Bacillus siralis (B. siralis).
Figure 3Flat dysplasia.
Colonic mucosa showing flat dysplasia. The sample was taken from an animal in group C.
Figure 4Dysplasia-associated lesion.
Colonic mucosa showing a dysplastic lesion in association with inflammation. The sample was taken from an animal in group C.
Figure 7Liver injury group C.
Focal parenchymal loss and haemorrhage in the liver of an animal in group C.
Figure 8Liver injury group P.
Hepatocytes showing displaced nucleus to the periphery, known as ballooning in an animal from group P.
Figure 9Liver injury group 2BP.
Parenchymal inflammatory infiltration in steatotic areas from an animal in group 2BP.
Figure 10Liver injury group 2B.
Parenchymal loss and haemorrhage in liver from an animal in group 2B.
Identification to species level of faecal lactobacilli.
| Group | Base line | After DSS cycle 1 | After DSS cycle 10 | Termination |
| C |
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
| |||
| P |
|
|
| |
|
|
| |||
| 2B |
|
|
|
|
|
|
| |||
|
|
| |||
|
| ||||
| 2BP |
|
|
|
|
|
|
|
| ||
|
|
| |||
| B |
|
|
|
|
|
|
|
| ||
|
|
| |||
|
| ||||
| BP |
|
|
|
|
|
|
| |||
|
|
| |||
|
|
Identification of isolates from viable count of faeces from the different groups of rats.
(L. = Lactobacillus).
SCFAs in colon content and blood samples.
| C | P | 2B | 2BP | B | BP | |
| Caecum | ||||||
| Acetic | 66.0a | 64.9 | 75.6b | 75.2 | 69.0a | 69.6 |
| Propionic | 16.9a | 16.1 | 15.1a,b | 14.8 | 13.5b | 12.9 |
| Butyric | 17.1a | 19.1 | 9.2b | 9.9 | 17.6a | 17.5 |
| Total (µmol/g) | 82.0a | 89.7 | 55.3b | 59.8 | 75.3a | 80.4 |
| Proximal colon | ||||||
| Acetic | 69.5a | 70.9 | 76.0b | 77.8 | 70.9a | 72.7 |
| Propionic | 16.1 | 13.6 | 15.2 | 13.5 | 13.4 | 11.8 |
| Butyric | 14.4a | 15.5 | 8.8b | 8.8 | 15.7a | 15.5 |
| Total (µmol/g) | 74.3a | 73.9 | 56.0b | 63.7 | 72.8a,b | 75.3 |
| Distal colon | ||||||
| Acetic | 66.4a | 66.0 | 73.1b | 73.0 | 67.5a | 69.5 |
| Propionic | 18.4 | 19.1 | 16.6 | 15.6 | 14.5 | 14.5 |
| Butyric | 15.3a | 14.9 | 10.3b | 11.5 | 18.0a | 16.0 |
| Total (µmol/g) | 75.0a | 75.8 | 38.6b | 47.6 | 82.1a | 70.5 |
| Blood from aorta | ||||||
| Acetic | 97.0 | 97.5 | 97.9 | 97.4* | 97.9 | 98.0 |
| Propionic | 1.1 | 0.7*** | 0.7 | 0.8** | 0.7 | 0.6 |
| Butyric | 1.9 | 1.8 | 1.5 | 1.8 | 1.4 | 1.4 |
Proportions (%) of acetic-, propionic- and butyric acids in the hindgut and blood of rats given diets supplemented with different amounts of blueberry husks (2B = 122 g blueberry/kg dwb and B = 61 g blueberry/kg dwb) and/or probiotics (P; 6⋅109 CFU per day).
Probiotics: Bifidobacterium infantis (CURE21), Lactobacillus gasseri VPG44, and Lactobacillus plantarum (HEAL19).
Mean values for eight rats per group, B group (n = 6).
Mean values of C, 2B and B only, i.e. those without any added probiotics, with unlike superscript letters were significantly different (P<0.05).
Mean values were significantly different from those rats fed diets without bacteria: *P<0.05, ** P<0.01, *** P<0.001.
2B (n = 7), B and BP (n = 6).